Online citations, reference lists, and bibliographies.
← Back to Search

Nitroreductase-activated Nitric Oxide (NO) Prodrugs.

Kavita Sharma, K. Sengupta, H. Chakrapani
Published 2013 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Due to the involvement of nitric oxide (NO) in numerous and diverse physiological processes, site-directed delivery of therapeutic NO in order to minimize unwanted side-effects is necessary. O(2)-(4-Nitrobenzyl) diazeniumdiolates are designed as substrates for Escherichia coli nitroreductase (NTR), an enzyme that is frequently used to facilitate directed delivery of cytotoxic species to cancers. O(2)-(4-Nitrobenzyl) diazeniumdiolates are found to be stable in aqueous buffer but are metabolized by NTR to produce NO. A cell viability assay revealed that cytotoxic effects of O(2)-(4-nitrobenzyl)1-(2-methylpiperidin-1-yl)diazen-1-ium-1,2-diolate (4b) towards two cancer cell lines is significantly enhanced in the presence of NTR suggesting the potential for use of this compound in nitric oxide-based directed prodrug therapy.
This paper references
10.1021/OL048397P
Sialated diazeniumdiolate: a new sialidase-activated nitric oxide donor.
T. B. Cai (2004)
10.1182/BLOOD-2006-10-052845
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
T. Kiziltepe (2007)
10.1021/ol8020989
Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.
H. Chakrapani (2008)
10.1021/JM9903850
Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: in vitro antileukemic activity.
J. Saavedra (2000)
10.1038/sj.cr.7290133
The role of nitric oxide in cancer
W. Xu (2002)
Hypoxic mammalian cell radiosensitization by nitric oxide.
J. Mitchell (1993)
10.1021/CR000028T
Chemistry of the nitric oxide-releasing diazeniumdiolate ("nitrosohydroxylamine") functional group and its oxygen-substituted derivatives.
J. Hrabie (2002)
Anti-Cancer Agents Med
J. E. Saavedra (2000)
10.1039/b903331a
The design, synthesis and evaluation of hypoxia-activated pro-oligonucleotides.
N. Zhang (2009)
10.1016/0006-2952(91)90100-J
Cytotoxicity and activation of CB1954 in a human tumour cell line.
A. Sunters (1991)
10.1016/J.BMCL.2005.12.089
Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy.
C. Asche (2006)
10.1021/JA002899Q
Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution.
K. M. Davies (2001)
10.1021/ol902481s
Glycosylated PROLI/NO derivatives as nitric oxide prodrugs.
R. Nandurdikar (2010)
10.1016/0959-8049(95)00436-X
Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
J. Bridgewater (1995)
10.1016/S0960-894X(99)00627-7
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT).
M. Hay (1999)
10.1021/JM960794L
Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
F. Friedlos (1997)
10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H
Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives
O. Greco (2001)
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
P. Shami (2003)
10.1021/cb200274r
Fifty Years of Diazeniumdiolate Research. From Laboratory Curiosity to Broad-Spectrum Biomedical Advances
L. Keefer (2011)
10.1021/ol400884v
INDQ/NO, a bioreductively activated nitric oxide prodrug.
Kavita Sharma (2013)
10.1016/j.bmcl.2009.03.115
Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
R. Nandurdikar (2009)
10.1021/OL701419A
V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO.
H. Chakrapani (2007)
10.1517/13543784.14.7.835
Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential
R. Scatena (2005)
10.1016/j.bmcl.2011.05.009
Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
L. Hu (2011)
10.1111/j.1742-4658.2011.08404.x
Substrate specificity of the deazaflavin‐dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles
M. Gurumurthy (2012)
Strategies for enzyme/prodrug cancer therapy.
G. Xu (2001)
Anticancer Agents Med
A. E. Maciag (2009)
10.1126/SCIENCE.1361684
NO news is good news.
E. Culotta (1992)
10.1211/jpp.59.1.0002
Targeting nitric oxide for cancer therapy
D. Hirst (2007)
10.1021/jm800831y
Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.
Daniela Andrei (2008)
10.1146/ANNUREV.PHARMTOX.43.100901.135831
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
L. Keefer (2003)
10.1038/nrc1367
Exploiting tumour hypoxia in cancer treatment
J. M. Brown (2004)
10.1021/OL7019636
Nitric oxide prodrugs: diazeniumdiolate anions of hindered secondary amines.
H. Chakrapani (2007)
10.1021/CR000040L
Nitric oxide donors: chemical activities and biological applications.
P. Wang (2002)
10.1124/jpet.110.174904
The Nitric Oxide Prodrug JS-K Is Effective against Non–Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species
Anna E. Maciag (2011)
10.3892/IJO_00000079
Nitric oxide donors: novel cancer therapeutics (review).
S. Huerta (2008)
10.1021/JM034133H
Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
L. Hu (2003)
10.1073/PNAS.95.13.7368
Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia.
K. Sogawa (1998)
10.1021/JM00047A002
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
A. Mauger (1994)
10.2174/187152009789056949
The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Anna E. Maciag (2009)
10.2741/2329
Targeting tumors with hypoxia-activated cytotoxins.
G-One Ahn (2007)
10.1021/jm8009102
Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
L. F. Tietze (2009)
10.1021/jm2004128
Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Anna E. Maciag (2011)
10.1016/J.FREERADBIOMED.2004.01.013
Mechanisms and novel directions in the biological applications of nitric oxide donors.
S. King (2004)
10.1016/j.bcp.2009.10.008
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
G. Prosser (2010)
10.3390/molecules14114517
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
G. Dachs (2009)
10.1021/jo802517t
C-nitroso donors of nitric oxide.
H. Chakrapani (2009)



This paper is referenced by
10.1007/978-3-319-13611-0_13
Emerging Role of NO-Mediated Therapeutics
C. McCrudden (2015)
Synthetic Materials with Redox-Triggers for Imaging and Drug Delivery
Jungeun Bae (2015)
A novel 3D PDAC model system developed with the use of decellularized matrix scaffolds
Ezekiel Rozmus (2019)
Title Development of photostabilized asymmetrical cyanine dyes forin vivo photoacoustic imaging of tumors
Satoru Onoe (2018)
10.1016/j.bioorg.2019.103318
Synthesis of novel nitroreductase enzyme-activated nitric oxide prodrugs to site-specifically kill bacteria.
Hailey A. J. Hibbard (2019)
10.1016/J.MTCOMM.2017.07.007
Functionalised solids delivering bioactive nitric oxide gas for therapeutic applications
Sharon Gregg (2017)
Fighting the Global Problem of Antimicrobial Resistance
Jennifer Claire Auer (2015)
10.1021/acs.orglett.6b02222
Design, Synthesis, and Evaluation of Diazeniumdiolate-Based DNA Cross-Linking Agents Activatable by Glutathione S-Transferase.
R. Xue (2016)
10.1002/cbic.201900614
Synthesis of Cyclic Sulfite Diesters and their Evaluation as Sulfur Dioxide (SO2) Donors
Satish R Malwal (2020)
10.1007/s40495-016-0073-y
Enzyme/Prodrug Systems for Cancer Gene Therapy
Obeid M. Malekshah (2016)
10.1021/acs.jmedchem.6b01672
Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
Zhangjian Huang (2017)
10.1002/ijch.202000084
From Spontaneous to Photo‐triggered and Photo‐calibrated Nitric Oxide Donors
Ziqian Zhang (2020)
10.1117/1.JBO.20.9.096006
Development of photostabilized asymmetrical cyanine dyes for in vivo photoacoustic imaging of tumors
Satoru Onoe (2015)
10.1002/advs.201701043
Progress and Promise of Nitric Oxide‐Releasing Platforms
T. Yang (2018)
10.1016/j.niox.2014.07.005
Site-directed delivery of nitric oxide to cancers.
Kavita Sharma (2014)
10.1002/adhm.202001550
Polymeric Nitric Oxide Delivery Nanoplatforms for Treating Cancer, Cardiovascular Diseases, and Infection.
Guorui Jin (2020)
10.1186/s12645-018-0040-x
Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer
C. McCrudden (2018)
10.3906/BIY-1507-143
Controlled nitric oxide release for tissue repair and regeneration
Y. Nie (2016)
10.1039/c9cc05266f
Novel α-ketoamide based diazeniumdiolates as hydrogen peroxide responsive nitric oxide donors with anti-lung cancer activity.
Junjie Fu (2019)
10.1021/ol5010643
Arylboronate ester based diazeniumdiolates (BORO/NO), a class of hydrogen peroxide inducible nitric oxide (NO) donors.
Allimuthu T. Dharmaraja (2014)
10.1039/C8RA03658F
Small molecule generators of biologically reactive sulfur species
Prerona Bora (2018)
10.1021/acs.orglett.6b00186
A Small Molecule for Controlled Generation of Peroxynitrite.
Vinayak S. Khodade (2016)
10.1002/cbic.201700155
FLUORO/NO: A Nitric Oxide Donor with a Fluorescence Reporter
G. Ravikumar (2017)
10.1002/smll.201907635
Enzyme Mimics for the Catalytic Generation of Nitric Oxide from Endogenous Prodrugs.
Tao Yang (2020)
10.1021/ol403300a
A small molecule for controlled generation of reactive oxygen species (ROS).
Allimuthu T. Dharmaraja (2014)
10.1016/j.addr.2017.06.013
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Raoul Walther (2017)
10.1016/j.omtn.2016.12.010
Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment
C. McCrudden (2017)
10.15226/2377-4274/1/1/00103
On Advances in Cancer Suicide-genes Therapy
A. Rama (2014)
10.1039/c4cc10345a
Real time detection of live microbes using a highly sensitive bioluminescent nitroreductase probe.
R. H. Wong (2015)
10.1002/smll.201906744
Zinc Oxide Particles Catalytically Generate Nitric Oxide from Endogenous and Exogenous Prodrugs.
Tao Yang (2020)
10.1080/17460441.2017.1344400
The latest advances in the discovery of nitric oxide hybrid drug compounds
R. A. M. Serafim (2017)
10.1016/j.ccr.2020.213460
Recent progress in the design principles, sensing mechanisms, and applications of small-molecule probes for nitroreductases
Yalin Qi (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar